Results 81 to 90 of about 8,545 (210)

Safety and efficacy of molnupiravir in SARS-CoV-2-infected patients: A real-life experience [PDF]

, 2022
Since the start of the severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) pandemic, several treatments have been proposed to cure coronavirus disease 2019 (COVID-19) and prevent it.
Babudieri, Sergio, Bacciu, Sara, Bitti, Alessandra, Colpani, Agnese, De Vito, Andrea, Denti, Lucia, Fois, Marco, Madeddu, Giordano, Maida, Ivana, Marcia, Claudia, Meloni, Maria Chiara, Zauli, Beatrice   +11 more
core   +1 more source

Impact of Early COVID‐19 Antiviral Therapy on the Incidence of Uveitis: A Retrospective Cohort Study Using the TriNetX Database

Immunity, Inflammation and Disease, Volume 14, Issue 5, May 2026.
ABSTRACT Objective To assess whether antivirals are associated with a reduced incidence of uveitis following COVID‐19. Methods We conducted a multi‐institutional, population‐based retrospective cohort study of adults (≥ 18 years) diagnosed with COVID‐19 between 2022 and 2024. Patients who received antiviral agents (Paxlovid, Molnupiravir, or Remdesivir)
Hou‐Ting Kuo, Alan Y. Hsu, De‐Yi Liu, Bing‐Qi Wu, James Cheng‐Chung Wei, Ning‐Yi Hsia, Yi‐Ching Shao, Chun‐Ting Lai, Chun‐Chi Chiang, Chun‐Ju Lin, Huan‐Sheng Chen, Yu‐Hsun Wang, Hsin Tseng, Ho‐Che Hsu, Yi‐Yu Tsai   +14 more
wiley   +1 more source

Molnupiravir plus usual care versus usual care alone as early treatment for adults with COVID-19 at increased risk of adverse outcomes (PANORAMIC): preliminary analysis from the united kingdom randomised, controlled open-label, platform adaptive trial [PDF]

, 2022
Background: The safety, effectiveness and cost-effectiveness of molnupiravir, an oral antiviral medication for SARS-CoV-2, in patients in the community who are multiply-vaccinated and at increased risk of morbidity and mortality from COVID-19, has not ...
Allen, Julie, Andersson, Monique, Barrett, Sarah, Bateman, Clare, Benysek, Magdalena, Berry, Nicholas, Breuer, Judith, Butler, Christopher, Butler, Daniel, Carson-Stevens, Andrew, Chalk, Jeremy, Coates, Maria, Cureton, Lucy, Davies, Jennifer, Detry, Michelle, Dobson, Melissa, Dorward, Jienchi, Evans, Philip, Fitzgerald, Mark, Francis, Nick, Galal, Ushma, Gbinigie, Oghenekome, Hadley, Elizabeth, Harris, Victoria, Hart, Nigel, Hayward, Gail, Hobbs, Richard, Holmes, Jane, Hood, Kerenza, Jani, Bhautesh, Khoo, Saye, Lavallee, Layla, Little, Paul, Lowe, David, Lown, Mark, Madden, Tracie-Ann, Marion, Joe, Mwandigha, Lazaro, Nguyen-Van-Tam, Jonathan S, Ogburn, Emma, Patel, Mahendra, Petrou, Stavros, Png, May Ee, Rahman, Najib M, Raymundo-Wood, Ivy, Richards, Duncan, Rutter, Heather, Saunders, Christina, Saville, Benjamin R, Standing, Joseph F, Thomas, Nicholas, Ustianowski, Andrew, van Hecke, Oliver, Yu, Ly-Mee   +53 more
core   +2 more sources

Carbohydrate‐Based Drug Discovery: Synthetic Strategies and Clinical Applications

Israel Journal of Chemistry, Volume 66, Issue 3, May 2026.
The picture depicts the molecules discussed in the review. On the left side, the general scaffold of sugars is shown. Next to it are four carbohydrate‐based molecules, including remdesivir, islatravir, empagliflozin, and Globo‐H. Remdesivir and islatravir contain a substituted ribose ring attached to a modified nucleobase.
Stephan Scheeff, Jemma Arakelyan, Billy Wai‐Lung Ng   +2 more
wiley   +1 more source

Small Molecule Inhibition of Mononegavirales RNA Polymerases

Journal of Medical Virology, Volume 98, Issue 5, May 2026.
ABSTRACT The order Mononegavirales includes several non‐segmented negative‐sense RNA viruses that are significant human pathogens, whose transcription and replication depend on multifunctional RNA‐dependent RNA polymerase (L protein). Recent discoveries in cryo‐electron microscopy (cryo‐EM) have elucidated the structures of these polymerases and their ...
Claire R. Cao, Meer Mohammed, Ge Yang, Dong Wang   +3 more
wiley   +1 more source

2‐Phenylquinolines Exhibit Anti‐Severe Acute Respiratory Syndrome Coronavirus‐2 Activity Through the Nonstructural Protein 13 Helicase Inhibition

ChemMedChem, Volume 21, Issue 7, 14 April 2026.
A SAR study led to the identification of new 2‐phenylquinoline‐based derivatives that exhibit anti‐Severe Acute Respiratory Syndrome Coronavirus‐2 (SARS‐CoV‐2) activity by acting as ATP‐competitive inhibitors of nonstructural protein 13 (nsp13) helicase.
Giada Cernicchi, Maria Giulia Nizi, Roberta Emmolo, Leentje Persoons, Manon Laporte, Dirk Jochmans, Isabella Romeo, Giacomo Pepe, Ciro Milite, Pietro Campiglia, Jacopo Spezzini, Alma Martelli, Simone Brogi, Francesca Esposito, Tommaso Felicetti, Serena Massari, Giuseppe Manfroni, Stefano Sabatini, Gianluca Sbardella, Stefano Alcaro, Johan Neyts, Angela Corona, Enzo Tramontano, Steven De Jonghe, Oriana Tabarrini   +24 more
wiley   +1 more source

Structure‐ and Ligand‐Based Discovery of Novel 3‐Chymotrypsin‐Like Protease Nonpeptidomimetic Hits

ChemMedChem, Volume 21, Issue 7, 14 April 2026.
A multistep virtual screening cascade, integrating shape‐based, ensemble docking, and quantitative structure–activity relationship (QSAR) models, was employed to screen 1.5 million compounds. This funnel identified a novel 3‐chymotrypsin‐like protease (3CLpro) inhibitor, LabMol‐499, which was experimentally validated using a Förster Resonance Energy ...
Sabrina Silva‐Mendonça, Donald Seanego, Christopher Jurisch, Melina Mottin, Flávia Nader Motta, Beatriz S. A. Rodrigues, Gilberto S. M. Junior, Alexandra Maria dos Santos Carvalho, Fábio Muniz de Oliveira, Sunniva Sigurdardóttir, Per Sunnerhagen, Izabela Marques Dourado Bastos, Richard Gessner, Kelly Chibale, Carolina Horta Andrade   +14 more
wiley   +1 more source

SARS-CoV-2 VOC type and biological sex affect molnupiravir efficacy in severe COVID-19 dwarf hamster model

Nature Communications, 2022
Molnupiravir was the first orally available SARS-CoV-2 antiviral approved for outpatient use against SARS-CoV-2, but its efficacy against variants of concern, especially delta, was questioned.
Carolin M. Lieber, Robert M. Cox, Julien Sourimant, Josef D. Wolf, Kate Juergens, Quynh Phung, Manohar T. Saindane, Meghan K. Smith, Zachary M. Sticher, Alexander A. Kalykhalov, Michael G. Natchus, George R. Painter, Kaori Sakamoto, Alexander L. Greninger, Richard K. Plemper   +14 more
doaj   +1 more source

A Bayesian Analysis of the Molnupiravir Trial Data

, 2021
On October 1st 2021, Merck issued a press release claiming that "molnupiravir (MK-4482, EIDD-2801), an investigational oral antiviral medicine, significantly reduced the risk of hospitalization or death at a planned interim analysis of the Phase 3 MOVe-OUT trial in at risk, non-hospitalized adult patients with mild-to-moderate COVID-19." Specifically ...
Eric-Jan Wagenmakers, Quentin Frederik Gronau   +1 more
openaire   +2 more sources

COVID‐19 Antiviral Treatment: Examining Knowledge, Access, Trust in Sources of Information and Willingness to Use Among Essential Workers: A Cross‐Sectional Survey of Cohort Participants

Health Science Reports, Volume 9, Issue 4, April 2026.
ABSTRACT Background and Aims Despite evidence of effectiveness, oral antivirals for COVID‐19 are underused, with significant variation across populations. This study examines COVID‐19 treatment awareness, knowledge, access, trusted sources, and willingness to use among diverse essential workers in Tennessee during May 18, 2023–June 1, 2024.
Jenae Sanders, Jade James‐Gist, Melisa M. Shah, Nathan Graff, Olivia Almendares, Tiffany Israel, Yuwei Zhu, Bryan Blette, Sarah Hamid, Hope King, H. Keipp Talbot, Carlos G. Grijalva, Melissa Briggs‐Hagen   +12 more
wiley   +1 more source